Clinical trials: Drug Interaction, open to volunteers
Healthy Volunteer, Pharmacokinetics
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
This is a Phase 1, open-label, three-part, study in approximately 96 healthy adult participants between 18 and 55 years of age (both inclusive) (16 participants in Part 1, 20 participants in Part 2 and , and approximately 60…
- Conditions
- Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI)
- Trial name
- NCT06733675
- Testing
- Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
PK Drug-drug Interaction Study
LTG-321 - Itraconazole Drug-drug Interaction (DDI) Study
This Phase 1, single-center, open-label, randomized, parallel-group study will evaluate the effect of itraconazole on the PK of LTG-321 and its metabolite(s), and the safety and tolerability of LTG-321 administered alone and in…
- Trial name
- NCT07915947
- Testing
- LTG-321, Itraconazole (200 mg)
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Latigo Biotherapeutics
Drug-drug Interaction
A Study to Learn About How Safe BAY3389934 is and How it Affects Blood Clotting When Given Alone or With Aspirin in Healthy Participants
The study treatment BAY3389934 is under development for people with blood clotting problems that occur due to sepsis. Sepsis is a serious condition that happens when the body's reaction to an infection causes organ damage.
- Trial name
- NCT07652723
- Testing
- Aspirin, BAY3389934
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib…
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
- Trial name
- STELLAR-002 (NCT05176483)
- Testing
- Zanzalintinib, Nivolumab, Ipilimumab
- Where
- 122 sites in United States, Australia and 11 more
- Volunteers
- 1,394 people
- Sponsor
- Exelixis
Drug-drug Interactions
A Clinical Trial to Evaluate the Drug-drug Interactions of Co-administered 'HUC2-744-A' and 'HUC2-744-B' in Healthy Adult Volunteers
This study aims to evaluate the pharmacokinetic interactions between HUC2-744-A and HUC2-744-B following monotherapy or co-administration under multiple-dose conditions.
- Trial name
- DDI (NCT07784608)
- Testing
- Atorvastatin Calcium, Telmisartan
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
DDI (Drug-Drug Interaction)
Drug-Drug Interaction Study of Vorolanib Tablets in Healthy Participants
This study adopts a single-center, open-label, same-subject sequential crossover clinical trial design, aiming to evaluate the effects of oral administration of rifampicin or itraconazole on the pharmacokinetic profiles of…
- Trial name
- NCT07809789
- Testing
- vorolanib and rifampicin, vorolanib and itraconazole
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
DDI (Drug-Drug Interaction)
Drug-Drug Interaction Study of Befotertinib Capsules in Healthy Participants.
This study adopts a single-center, open-label, same-subject sequential crossover clinical trial design, aiming to evaluate the effects of oral administration of rifampicin or itraconazole on the pharmacokinetic profiles of…
- Trial name
- NCT07809815
- Testing
- Befotertinib and rifampicin, Befotertinib and itraconazole
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Drug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
This is a Phase I, open-label, two-cohort study designed to evaluate the drug-drug interaction potential of multiple-dose UBT251 Injection in adult participants with overweight or obesity.
- Trial name
- NCT07785934
- Testing
- UBT251, Metformin hydrochloride, Warfarin Sodium
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Drug Interaction Research
Clinical Study on Drug Interactions of Flonoltinib Maleate Tablets
This study is a single center, open label, fixed sequence drug interaction study to evaluate the effects of CYP3A4 inhibitor itraconazole and CYP3A4 inducer rifampicin on the pharmacokinetic characteristics of a single oral dose…
- Trial name
- NCT07768111
- Testing
- 75mg Flonoltinib, 100mg Flonoltinib
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Drug Drug Interaction (DDI)
Study on the Drug Interaction Between Buagafuran and Voriconazole
This study is a non-randomized, open label trial aimed at evaluating the drug interaction between Buagafuran capsules and voriconazole tablets in Chinese adult healthy participants.The research period is 7 days in total.
- Trial name
- NCT07457203
- Testing
- Buagafuran, Voriconazole
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Beijing Union Pharmaceutical Factory Ltd
Drug-drug Interaction Study
Drug-drug Interaction Study of Rifampin and Anaprazole Sodium
A drug-drug interaction study designed to evaluate the drug-drug interaction between rifampin capsules and anaprazole sodium enteric-coated tablets in healthy adult subjects
- Trial name
- NCT07330531
- Testing
- Anelazol Sodium Enteric-coated Tablets, Rifampicin Capsules
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Drug Drug Interaction (DDI)
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
- Trial name
- NCT07265466
- Testing
- JP-1366 and clopidogrel, JP-1366 and aspirin, JP-1366 and atorvastatin
- Where
- South Korea
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Onconic Therapeutics Inc.